The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Nanopharmaceuticals are colloidal particles of 10 to 1,000 nanometers (1 micron) in size. They are widely used in drug delivery.
Nanopharmaceuticals are diverse both in their shape and composition and often offer an advantage as compared to their “bulk” counterparts primarily because of size.
There are two types of nanopharmaceuticals: (1) those where the therapeutic molecules are themselves the drug (i.e.,the therapeutic compound itself also functions as its own carrier); and (2) those where the therapeutic molecules are directly coupled (functionalized, entrapped, or coated) to a nanoparticle carrier.
The global Nanopharmaceuticals market was valued at US$ 30960 million in 2023 and is anticipated to reach US$ 73550 million by 2030, witnessing a CAGR of 13.0% during the forecast period 2024-2030.
USA is the largest Nanopharmaceuticals market with about 59% market share. Europe is follower, accounting for about 33% market share.
The key players are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy etc. Top 3 companies occupied about 34% market share.
This report aims to provide a comprehensive presentation of the global market for Nanopharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanopharmaceuticals.
Report Scope
The Nanopharmaceuticals market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nanopharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nanopharmaceuticals manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company (Partial List)
- Merck
- Pfizer
- Novartis
- Abbott
- GlaxoSmithKline
- Roche
- Sanofi
- Eli Lilly
- Astrazeneca
- Johnson & Johnson
- Celgene
- Novavax
- Stryker
- Gilead Sciences
- OSI Pharmaceuticals
- Kadmon Pharmaceuticals
- Samyang Biopharm
- Mitsubishi Pharma
- Kaken Pharmaceutical
- Selecta Biosciences
- Par Pharmaceutical
- Cerulean Pharma
- Navidea Biopharmaceuticals
- Lummy
Segment by Type
- Liposomes
- Polymeric Micelles
- Solid Lipid Nanoparticles
- Microemulsion and Nnanoemulsion
- Nanosuspension
Segment by Application
- Cancer and Tumor
- Autoimmune Disorders
- Inflammation
- Others
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nanopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nanopharmaceuticals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Nanopharmaceuticals Market Overview
1.1 Product Overview and Scope of Nanopharmaceuticals
1.2 Nanopharmaceuticals Segment by Type
1.2.1 Global Nanopharmaceuticals Market Value Comparison by Type (2024-2030)
1.2.2 Liposomes
1.2.3 Polymeric Micelles
1.2.4 Solid Lipid Nanoparticles
1.2.5 Microemulsion and Nnanoemulsion
1.2.6 Nanosuspension
1.3 Nanopharmaceuticals Segment by Application
1.3.1 Global Nanopharmaceuticals Market Value by Application: (2024-2030)
1.3.2 Cancer and Tumor
1.3.3 Autoimmune Disorders
1.3.4 Inflammation
1.3.5 Others
1.4 Global Nanopharmaceuticals Market Size Estimates and Forecasts
1.4.1 Global Nanopharmaceuticals Revenue 2019-2030
1.4.2 Global Nanopharmaceuticals Sales 2019-2030
1.4.3 Global Nanopharmaceuticals Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Nanopharmaceuticals Market Competition by Manufacturers
2.1 Global Nanopharmaceuticals Sales Market Share by Manufacturers (2019-2024)
2.2 Global Nanopharmaceuticals Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Nanopharmaceuticals Average Price by Manufacturers (2019-2024)
2.4 Global Nanopharmaceuticals Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nanopharmaceuticals, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nanopharmaceuticals, Product Type & Application
2.7 Nanopharmaceuticals Market Competitive Situation and Trends
2.7.1 Nanopharmaceuticals Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Nanopharmaceuticals Players Market Share by Revenue
2.7.3 Global Nanopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Nanopharmaceuticals Retrospective Market Scenario by Region
3.1 Global Nanopharmaceuticals Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Nanopharmaceuticals Global Nanopharmaceuticals Sales by Region: 2019-2030
3.2.1 Global Nanopharmaceuticals Sales by Region: 2019-2024
3.2.2 Global Nanopharmaceuticals Sales by Region: 2025-2030
3.3 Global Nanopharmaceuticals Global Nanopharmaceuticals Revenue by Region: 2019-2030
3.3.1 Global Nanopharmaceuticals Revenue by Region: 2019-2024
3.3.2 Global Nanopharmaceuticals Revenue by Region: 2025-2030
3.4 North America Nanopharmaceuticals Market Facts & Figures by Country
3.4.1 North America Nanopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Nanopharmaceuticals Sales by Country (2019-2030)
3.4.3 North America Nanopharmaceuticals Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Nanopharmaceuticals Market Facts & Figures by Country
3.5.1 Europe Nanopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Nanopharmaceuticals Sales by Country (2019-2030)
3.5.3 Europe Nanopharmaceuticals Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nanopharmaceuticals Market Facts & Figures by Country
3.6.1 Asia Pacific Nanopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Nanopharmaceuticals Sales by Country (2019-2030)
3.6.3 Asia Pacific Nanopharmaceuticals Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Nanopharmaceuticals Market Facts & Figures by Country
3.7.1 Latin America Nanopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Nanopharmaceuticals Sales by Country (2019-2030)
3.7.3 Latin America Nanopharmaceuticals Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Nanopharmaceuticals Market Facts & Figures by Country
3.8.1 Middle East and Africa Nanopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Nanopharmaceuticals Sales by Country (2019-2030)
3.8.3 Middle East and Africa Nanopharmaceuticals Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Nanopharmaceuticals Sales by Type (2019-2030)
4.1.1 Global Nanopharmaceuticals Sales by Type (2019-2024)
4.1.2 Global Nanopharmaceuticals Sales by Type (2025-2030)
4.1.3 Global Nanopharmaceuticals Sales Market Share by Type (2019-2030)
4.2 Global Nanopharmaceuticals Revenue by Type (2019-2030)
4.2.1 Global Nanopharmaceuticals Revenue by Type (2019-2024)
4.2.2 Global Nanopharmaceuticals Revenue by Type (2025-2030)
4.2.3 Global Nanopharmaceuticals Revenue Market Share by Type (2019-2030)
4.3 Global Nanopharmaceuticals Price by Type (2019-2030)
5 Segment by Application
5.1 Global Nanopharmaceuticals Sales by Application (2019-2030)
5.1.1 Global Nanopharmaceuticals Sales by Application (2019-2024)
5.1.2 Global Nanopharmaceuticals Sales by Application (2025-2030)
5.1.3 Global Nanopharmaceuticals Sales Market Share by Application (2019-2030)
5.2 Global Nanopharmaceuticals Revenue by Application (2019-2030)
5.2.1 Global Nanopharmaceuticals Revenue by Application (2019-2024)
5.2.2 Global Nanopharmaceuticals Revenue by Application (2025-2030)
5.2.3 Global Nanopharmaceuticals Revenue Market Share by Application (2019-2030)
5.3 Global Nanopharmaceuticals Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Nanopharmaceuticals Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Nanopharmaceuticals Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Novartis Nanopharmaceuticals Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Abbott
6.4.1 Abbott Corporation Information
6.4.2 Abbott Description and Business Overview
6.4.3 Abbott Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Abbott Nanopharmaceuticals Product Portfolio
6.4.5 Abbott Recent Developments/Updates
6.5 GlaxoSmithKline
6.5.1 GlaxoSmithKline Corporation Information
6.5.2 GlaxoSmithKline Description and Business Overview
6.5.3 GlaxoSmithKline Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GlaxoSmithKline Nanopharmaceuticals Product Portfolio
6.5.5 GlaxoSmithKline Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Roche Nanopharmaceuticals Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Nanopharmaceuticals Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Eli Lilly
6.8.1 Eli Lilly Corporation Information
6.8.2 Eli Lilly Description and Business Overview
6.8.3 Eli Lilly Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Eli Lilly Nanopharmaceuticals Product Portfolio
6.8.5 Eli Lilly Recent Developments/Updates
6.9 Astrazeneca
6.9.1 Astrazeneca Corporation Information
6.9.2 Astrazeneca Description and Business Overview
6.9.3 Astrazeneca Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Astrazeneca Nanopharmaceuticals Product Portfolio
6.9.5 Astrazeneca Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Corporation Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Johnson & Johnson Nanopharmaceuticals Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 Celgene
6.11.1 Celgene Corporation Information
6.11.2 Celgene Nanopharmaceuticals Description and Business Overview
6.11.3 Celgene Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Celgene Nanopharmaceuticals Product Portfolio
6.11.5 Celgene Recent Developments/Updates
6.12 Novavax
6.12.1 Novavax Corporation Information
6.12.2 Novavax Nanopharmaceuticals Description and Business Overview
6.12.3 Novavax Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Novavax Nanopharmaceuticals Product Portfolio
6.12.5 Novavax Recent Developments/Updates
6.13 Stryker
6.13.1 Stryker Corporation Information
6.13.2 Stryker Nanopharmaceuticals Description and Business Overview
6.13.3 Stryker Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Stryker Nanopharmaceuticals Product Portfolio
6.13.5 Stryker Recent Developments/Updates
6.14 Gilead Sciences
6.14.1 Gilead Sciences Corporation Information
6.14.2 Gilead Sciences Nanopharmaceuticals Description and Business Overview
6.14.3 Gilead Sciences Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Gilead Sciences Nanopharmaceuticals Product Portfolio
6.14.5 Gilead Sciences Recent Developments/Updates
6.15 OSI Pharmaceuticals
6.15.1 OSI Pharmaceuticals Corporation Information
6.15.2 OSI Pharmaceuticals Nanopharmaceuticals Description and Business Overview
6.15.3 OSI Pharmaceuticals Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.15.4 OSI Pharmaceuticals Nanopharmaceuticals Product Portfolio
6.15.5 OSI Pharmaceuticals Recent Developments/Updates
6.16 Kadmon Pharmaceuticals
6.16.1 Kadmon Pharmaceuticals Corporation Information
6.16.2 Kadmon Pharmaceuticals Nanopharmaceuticals Description and Business Overview
6.16.3 Kadmon Pharmaceuticals Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Kadmon Pharmaceuticals Nanopharmaceuticals Product Portfolio
6.16.5 Kadmon Pharmaceuticals Recent Developments/Updates
6.17 Samyang Biopharm
6.17.1 Samyang Biopharm Corporation Information
6.17.2 Samyang Biopharm Nanopharmaceuticals Description and Business Overview
6.17.3 Samyang Biopharm Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Samyang Biopharm Nanopharmaceuticals Product Portfolio
6.17.5 Samyang Biopharm Recent Developments/Updates
6.18 Mitsubishi Pharma
6.18.1 Mitsubishi Pharma Corporation Information
6.18.2 Mitsubishi Pharma Nanopharmaceuticals Description and Business Overview
6.18.3 Mitsubishi Pharma Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Mitsubishi Pharma Nanopharmaceuticals Product Portfolio
6.18.5 Mitsubishi Pharma Recent Developments/Updates
6.19 Kaken Pharmaceutical
6.19.1 Kaken Pharmaceutical Corporation Information
6.19.2 Kaken Pharmaceutical Nanopharmaceuticals Description and Business Overview
6.19.3 Kaken Pharmaceutical Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Kaken Pharmaceutical Nanopharmaceuticals Product Portfolio
6.19.5 Kaken Pharmaceutical Recent Developments/Updates
6.20 Selecta Biosciences
6.20.1 Selecta Biosciences Corporation Information
6.20.2 Selecta Biosciences Nanopharmaceuticals Description and Business Overview
6.20.3 Selecta Biosciences Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Selecta Biosciences Nanopharmaceuticals Product Portfolio
6.20.5 Selecta Biosciences Recent Developments/Updates
6.21 Par Pharmaceutical
6.21.1 Par Pharmaceutical Corporation Information
6.21.2 Par Pharmaceutical Nanopharmaceuticals Description and Business Overview
6.21.3 Par Pharmaceutical Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Par Pharmaceutical Nanopharmaceuticals Product Portfolio
6.21.5 Par Pharmaceutical Recent Developments/Updates
6.22 Cerulean Pharma
6.22.1 Cerulean Pharma Corporation Information
6.22.2 Cerulean Pharma Nanopharmaceuticals Description and Business Overview
6.22.3 Cerulean Pharma Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Cerulean Pharma Nanopharmaceuticals Product Portfolio
6.22.5 Cerulean Pharma Recent Developments/Updates
6.23 Navidea Biopharmaceuticals
6.23.1 Navidea Biopharmaceuticals Corporation Information
6.23.2 Navidea Biopharmaceuticals Nanopharmaceuticals Description and Business Overview
6.23.3 Navidea Biopharmaceuticals Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Navidea Biopharmaceuticals Nanopharmaceuticals Product Portfolio
6.23.5 Navidea Biopharmaceuticals Recent Developments/Updates
6.24 Lummy
6.24.1 Lummy Corporation Information
6.24.2 Lummy Nanopharmaceuticals Description and Business Overview
6.24.3 Lummy Nanopharmaceuticals Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Lummy Nanopharmaceuticals Product Portfolio
6.24.5 Lummy Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nanopharmaceuticals Industry Chain Analysis
7.2 Nanopharmaceuticals Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nanopharmaceuticals Production Mode & Process
7.4 Nanopharmaceuticals Sales and Marketing
7.4.1 Nanopharmaceuticals Sales Channels
7.4.2 Nanopharmaceuticals Distributors
7.5 Nanopharmaceuticals Customers
8 Nanopharmaceuticals Market Dynamics
8.1 Nanopharmaceuticals Industry Trends
8.2 Nanopharmaceuticals Market Drivers
8.3 Nanopharmaceuticals Market Challenges
8.4 Nanopharmaceuticals Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
